Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (41-50 of 203) with videos related to

Pageof 21
Sort By:
Leukemia & Lymphoma|October 27, 2021
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignanciesStephen Jolles, B Douglas Smith, Donald C Vinh, et al.
Leukemia Research|November 21, 2020
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypesBreann Yanagisawa, Brandy Perkins, Theodoros Karantanos, et al.
Head and Neck Pathology|February 22, 2021
Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad MassAmy S Duffield, Jonathan Webster, B Douglas Smith, et al.
British Journal of Haematology|October 30, 2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasiaAmer M Zeidan, B Douglas Smith, Hetty E Carraway, et al.
Current Medical Research and Opinion|March 23, 2018
Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug developmentJaein Seo, B Douglas Smith, Elihu Estey, et al.
Leukemia & Lymphoma|April 10, 2014
The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?Joshua F Zeidner, Marianna Zahurak, Gary L Rosner, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2017
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and ManagementJorge E Cortes, Carlos A Jimenez, Michael J Mauro, et al.
Investigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.
Leukemia Research|August 20, 2025
Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trialAmir T Fathi, B Douglas Smith, Anne Angiolillo, et al.
British Journal of Haematology|March 10, 2005
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemiaWilliam Matsui, B Douglas Smith, Milada Vala, et al.
Pageof 21

Showing results (41-50 of 203) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|October 27, 2021
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignanciesStephen Jolles, B Douglas Smith, Donald C Vinh, et al.
Leukemia Research|November 21, 2020
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypesBreann Yanagisawa, Brandy Perkins, Theodoros Karantanos, et al.
Head and Neck Pathology|February 22, 2021
Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad MassAmy S Duffield, Jonathan Webster, B Douglas Smith, et al.
British Journal of Haematology|October 30, 2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasiaAmer M Zeidan, B Douglas Smith, Hetty E Carraway, et al.
Current Medical Research and Opinion|March 23, 2018
Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug developmentJaein Seo, B Douglas Smith, Elihu Estey, et al.
Leukemia & Lymphoma|April 10, 2014
The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?Joshua F Zeidner, Marianna Zahurak, Gary L Rosner, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2017
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and ManagementJorge E Cortes, Carlos A Jimenez, Michael J Mauro, et al.
Investigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.
Leukemia Research|August 20, 2025
Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trialAmir T Fathi, B Douglas Smith, Anne Angiolillo, et al.
British Journal of Haematology|March 10, 2005
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemiaWilliam Matsui, B Douglas Smith, Milada Vala, et al.
Pageof 21